[Experience in treating osseous sarcomas at the Research Institute of Pediatric Oncology, Cancer Research Center]

The paper presents clinical findings of 210 children with localized osteogenic sarcoma who have undergone various treatments. The authors consider neoadjuvant chemotherapy the method of choice, but by replacing tubular bone defects, endoprosthesis should be regarded the method of choice, which substantially reduces the time of rehabilitation and yields good (32.4%) and satisfactory (47.0%) functional results in most patients. In children with osteogenic sarcomas, the outcomes of treatment depend on its scope: 5-year survival was achieved in 68% of cases following multimodality treatment and in 36.2 and 14.0% after combined treatment and monotherapy alone, respectively. The retrospective analysis of treatment for morphologically verified Jung's sarcoma shows it expedient to implement a comprehensive program, including cyclic polychemotherapy, radiation of a damage focus in a dose of 57 Gy, obligatory surgical intervention into the operable sites, by assessing therapeutical pathomorphism and subsequent adjuvant polychemotherapy for at least 12-18 months.